#1 Clinical Trials Search in Europe

Rineterkib

This article discusses the use of Rineterkib, a new drug being studied in clinical trials for the treatment of myelofibrosis. Rineterkib is being tested in combination with ruxolitinib, an existing treatment for myelofibrosis, to assess its safety, effectiveness, and potential benefits for patients with this rare blood disorder. The ongoing research aims to provide new treatment options and improve outcomes for those affected by myelofibrosis.

Table of Contents

What is Rineterkib?

Rineterkib, also known by its alternative name LTT462, is a new medication being studied for the treatment of myelofibrosis[1]. It is currently in the experimental stage and is being tested in clinical trials to determine its safety and effectiveness. Rineterkib comes in the form of 100 mg capsules that are taken orally[1].

What is Myelofibrosis?

Myelofibrosis is a rare type of blood cancer that affects the bone marrow, which is the soft tissue inside our bones where blood cells are made. In myelofibrosis, the bone marrow is replaced by scar tissue, leading to problems with blood cell production. This can cause various symptoms such as fatigue, weakness, and an enlarged spleen[1].

How is Rineterkib Used?

In the ongoing clinical trial, Rineterkib is being tested in combination with another drug called ruxolitinib. Ruxolitinib is an already approved treatment for myelofibrosis. The researchers are investigating whether adding Rineterkib to ruxolitinib can improve the treatment outcomes for patients with myelofibrosis[1].

Clinical Trial Information

Rineterkib is currently being studied in a clinical trial called “Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients” (NCT04097821). This trial is designed to test several new drugs, including Rineterkib, in combination with ruxolitinib. The study is divided into three parts[1]:

  • Part 1: This is the initial phase where researchers are testing different doses of Rineterkib with ruxolitinib to determine the safest and most effective dose combination.
  • Part 2: In this phase, the selected dose of Rineterkib is given to a larger group of patients to further assess its effectiveness and safety.
  • Part 3: This phase was planned to expand the study if the results from Part 2 were promising. However, as of June 2022, the study enrollment was halted, and Part 3 will not be initiated.

Potential Benefits

While the full benefits of Rineterkib are still being studied, the researchers are looking at several potential improvements for patients with myelofibrosis[1]:

  • Improved anemia: They are checking if the treatment can increase hemoglobin levels, which could help reduce fatigue and weakness.
  • Reduced spleen size: The study is measuring changes in spleen volume, as an enlarged spleen is a common problem in myelofibrosis.
  • Symptom relief: Researchers are using questionnaires to assess if the treatment improves symptoms like night sweats, itching, and abdominal discomfort.
  • Improved bone marrow health: They are looking at whether the treatment can reduce the scarring in the bone marrow.

Safety and Side Effects

As Rineterkib is still in the testing phase, its full safety profile is not yet known. The clinical trial is carefully monitoring patients for any side effects or adverse reactions. One of the main goals of the study is to determine the “dose-limiting toxicities,” which are side effects severe enough to prevent increasing the dose further[1].

It’s important to note that as an experimental treatment, Rineterkib is only available to patients participating in clinical trials. If you have myelofibrosis and are interested in this treatment, you should discuss with your doctor whether participating in a clinical trial might be appropriate for you.

Aspect Details
Drug Name Rineterkib (LTT462)
Condition Studied Myelofibrosis
Study Type Phase I/II clinical trial
Combination Therapy Rineterkib + Ruxolitinib
Administration 100 mg capsule for oral use
Primary Outcomes Safety, tolerability, and initial efficacy
Secondary Outcomes Changes in spleen volume, hemoglobin levels, symptom scores, quality of life, and progression-free survival
Study Duration Up to 48 weeks or longer
Key Assessments Spleen volume, blood counts, symptom scores, quality of life questionnaires

FAQ

  • What is Rineterkib? Rineterkib, also known as LTT462, is a new drug being studied in clinical trials for the treatment of myelofibrosis. It is administered as a 100 mg capsule for oral use.
  • How is Rineterkib being studied in clinical trials? Rineterkib is being studied in combination with ruxolitinib, an existing treatment for myelofibrosis. The trial involves a dose escalation phase where Rineterkib is added to a stable dose of ruxolitinib to assess safety, tolerability, and to determine the recommended dose for further study.
  • What are the main goals of the clinical trial involving Rineterkib? The main goals of the trial are to investigate the safety, how the drug behaves in the body (pharmacokinetics), and initial effectiveness of the combination treatment of ruxolitinib with Rineterkib in patients with myelofibrosis.
  • What outcomes are being measured in the Rineterkib clinical trial? The trial is measuring various outcomes, including changes in spleen volume, improvements in blood counts (particularly hemoglobin levels), changes in myelofibrosis symptoms, quality of life, and progression-free survival.
  • How long does the Rineterkib clinical trial last? The duration of the trial varies depending on the phase, but it can last up to 48 weeks (about 1 year) or longer. Specific assessments are made at various time points, such as at 24 weeks and 48 weeks after starting treatment.

Ongoing Clinical Trials on Rineterkib

  • Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

Glossary

  • Myelofibrosis: A rare blood disorder where scar tissue forms in the bone marrow, leading to decreased blood cell production and various symptoms such as fatigue, enlarged spleen, and anemia.
  • Ruxolitinib: An existing medication used to treat myelofibrosis, administered as 5 mg tablets for oral use. It's also known by the brand names Jakavi or INC424.
  • Rineterkib: A new drug being studied for myelofibrosis treatment, also known as LTT462, administered as 100 mg capsules for oral use.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Dose escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.
  • Spleen volume: A measure of spleen size, often increased in myelofibrosis patients, used to assess disease progression and treatment effectiveness.
  • Hemoglobin: A protein in red blood cells that carries oxygen. Improving hemoglobin levels is a goal in myelofibrosis treatment.
  • Progression-free survival: The length of time during and after treatment that a patient lives without the disease getting worse.
  • MFSAF v4.0: Myelofibrosis Symptom Assessment Form version 4.0, a questionnaire used to assess the severity of myelofibrosis symptoms.
  • EORTC QLQ-C30: European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire, used to assess quality of life in cancer patients.

References

  1. https://clinicaltrials.gov/study/NCT04097821